Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenetic Biosciences (XBIO – Research Report) and Dianthus Therapeutics (DNTH – Research Report).
Xenetic Biosciences (XBIO)
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Xenetic Biosciences today. The company’s shares closed last Thursday at $3.95.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Xenetic Biosciences has an analyst consensus of Hold.
See today’s best-performing stocks on TipRanks >>
Dianthus Therapeutics (DNTH)
Wedbush analyst Laura Chico maintained a Buy rating on Dianthus Therapeutics today and set a price target of $33.00. The company’s shares closed last Thursday at $27.94, close to its 52-week high of $30.77.
According to TipRanks.com, Chico is a 4-star analyst with an average return of
Currently, the analyst consensus on Dianthus Therapeutics is a Strong Buy with an average price target of $33.00, implying a 21.5% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $44.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XBIO:
